Dr Akshaya

Tranquil Artist 🌸 | Consultant Hematopathologist & Head, Dept of Hematopathology & Flowcytometry @ Agilus Diagnostics ( formerly SRL) , Reference Lab, Mumbai

[Dr Akshaya @_DrAkshaya]

@DrArunCMC @ASH_hematology Wow! Heartiest congratulations!💐💐

[Abdul Muqtadir Abbasi @AbbasiMuqtadir]

Residents!!! Here comes vwd cheat sheet.

#MedTwitter

[ICCS_Education @ICCS_Education]

Mechanisms of CD19 loss due to CD19-directed therapies. It's important to use multiple B-cell antigens and gating strategies to avoid missing these populations. From the plenary session talk by Erik Ames at #FlowICCS25
#FlowEdu #HemePath

[Manual Of Medicine @ManualOMedicine]

Anticoagulation Cheat Sheet

#medtwitter #foamed #usmle

[William Aird @WilliamAird4]

ISOLATED NEUTROPENIA

Saw a young white man in clinic today with isolated neutropenia. Went to brush up…and was struck by how little we actually know about this condition compared to anemia or thrombocytopenia. A diagnostic blind spot in hematology.

See: https://t.co/ESa7MjSbCP

[William Aird @WilliamAird4]

1/4

MILD, MODERATE, SEVERE... ACCORDING TO WHO?

I often notice MDs describing cytopenias as “mild,” “moderate,” or “severe” without reference to standard definitions.

The problem? Severity is in the eye of the beholder. Without shared definitions, these terms lose precision.

[Ahmed Kotb @AhmedKo45911157]

1 Acute myeloid leukemia (AML), blast morphology often provides important clues to the underlying genetics

[Andreas Hochhaus @AndreasHochhaus]

Just published: on behalf of the European LeukemiaNet, the international expert panel led by Prof Jane Apperley presented the 2025 management recommendations of chronic myeloid leukemia (CML) in LEUKEMIA @LeukemiaJnl open access.

https://t.co/m97NicZLcC

[Vincent Rajkumar @VincentRK]

Just out: Mayo Clinic mSMART Risk Stratification of Myeloma
#EHA25

1/ We recommend and use same high risk cytogenetic definition as the latest IMS/IMWG paper

2/ Primary plasma cell leukemia is high risk myeloma

3/ We define Double-hit high risk myeloma

https://t.co/R4hz7umwEJ

[Thulasi Raman @Thulas31081987]

But cytology has drawbacks like low sensitivity, subjectivity, sampling error, and pressure of reporting against time. Is there any better technique?
🤔
Happy to share our recent article “Intraoperative flow cytometry in Gastric cancer” in Cytometry B
👇🏻
https://t.co/gOktTraMbw

[DR. ASISH RATH @asishdoct]

Excited to host TCS-2025 (Annual workshops and conference of The Cytometry Society, India) in the City of JoY. SAVE THE DATES AND JOIN US IN THIS ACADEMIC EXTRAVAGANZA!!!!
#FLOWTCS2025
@CytometryIndia
@DrArunCMC @PrashantTembha1 @drdatari @drkunalsehgal @SSVinarkar

[Dr Akshaya @_DrAkshaya]

Great read

https://t.co/CtaI3EJah5

[Thulasi Raman @Thulas31081987]

Inotuzumab ozogamicin (INO) being an anti CD22 therapy, Which of these ����🏻refractory/Relapsed B-ALL patients are ideal for INO therapy.

Red - Blast.
Blue - Normal B lymphocytes.
Green - Normal T lymphocytes.

[William Aird @WilliamAird4]

RELATIONSHIPS BETWEEN RBC INDICES

Contextualizing:
RBC count
Hct
Hb
MCV
MCHC

... notice how MCH not included - it is NOT helpful!

[Sanam Loghavi, MD صنم لغوی 🔬🧬 @sanamloghavi]

This is it people…. It’s really happening
One unified #hemepath classification in the works…WHO 6th coming to you soon

@SocforHemepath #USCAP2025

[ICCS_Education @ICCS_Education]

What is a blast?🤔
This is a deceptively simple question but the latest module from the ICCS Q&S Committee has all the answers! Get tips & detailed tables to identify normal & abnormal blast populations, and learn about potential pitfalls.
Check it out⬇️
https://t.co/yxIpUlEmcp

[Uday Yanamandra @UdayYanamandra]

Join us (@IndMyAcGp) on 26 Dec 2024 Journal Club to discuss the role of Mass Spec & NGF in Multiple Myeloma MRD, followed by a Quiz. Also, send your commentaries for the Eagle Eye Competition (the date is extended till 22 Dec 2024). @DrPMPGI @MirghSumeet @DrAnilHandoo @NoemiPuigM

[Vincent Rajkumar @VincentRK]

My Annual Updated Myeloma Treatment Algorithms thread. Bookmark! #ASH24
#ASH24VR

1. Newly diagnosed transplant ineligible. Quadruplet unless frail. Maintenance varies by risk stratification.

[Vincent Rajkumar @VincentRK]

For #ASH24. Active myeloma drugs in one table with mechanism of action. Bookmark!

Black font — Approved drugs
Blue font — Investigational
#ASH24VR

[Tata Memorial Hospital @TataMemorial]

@ACTREC_TMC @TMC_Varanasi @hbchsangrur @HBCHRC_Punjab @HBCHRCVIZAG @BorooahDr

[Bruno Paiva @BrunoPaiva_UNAV]

🚨New paper alert🚨
The prognostic value of MRD after CAR T cells and T cell engagers remained uncertain. Our study @AjHematology shows that MRD negative CR is the most relevant prognostic factor in this setting!
#mmsm
@ClinicaNavarra @CIMA_unav @_pethema
https://t.co/AMtLfCZfis